Allelic and functional variability of cytochrome P4502C9

Pharmacogenetics

Volumn 7, Issue 1, 1997, Pages 51-58

  Bhasker, C Ramana ^a   Miners, John O ^a   Coulter, Sally ^a   Birkett, Donald J ^a  

^a FLINDERS UNIVERSITY   (Australia)

Author keywords

allele specific expression; CYP2C9; polymorphism; tolbutamide

Indexed keywords

CYTOCHROME P450; DICLOFENAC; PHENYTOIN; TOLBUTAMIDE; TORASEMIDE;

ALLELE; ARTICLE; DRUG METABOLISM; ENZYME ACTIVITY; GENE EXPRESSION; GENETIC POLYMORPHISM; GENOME; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; HYDROXYLATION; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

ALLELES; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 ENZYME SYSTEM; DNA PRIMERS; HETEROZYGOTE; HOMOZYGOTE; HUMANS; MICROSOMES, LIVER; POINT MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; STEROID 16-ALPHA-HYDROXYLASE; STEROID HYDROXYLASES; TOLBUTAMIDE; VARIATION (GENETICS);

EID: 0030947801     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-199702000-00007     Document Type: Article

References (34)

1. Brian WR, Srivastava PK, Umbenhauer DR, Lloyd RS, Guengerich FP. Expression of a human liver cytochrome P450 protein with tolbutamide hydroxylase activity in Saccaromyces cerevisiae. Biochemistry 1989: 28, 4993-4999.
2. Chomczynski P, Sacchi N. Single-Step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987: 162, 156-159.
3. Doecke CJ, Sansom LN, McManus ME. Phenytoin 4-hydroxylation by rabbit liver P450IIC3 and identification of orthologs in human liver microsomes. Biochem Biophys Res Commun 1990: 166, 860-866.
4. Furuya H, Fernandez-Salguero P, Gregory W, Taber H, Steward A, Gonzalez FJ, Idle JR. Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy. Pharmacogentics 1995: 5, 389-392.
5. Holford NGH, MK Model: a modelling tool for microcomputers. Pharmacokinelic and evaluation and comparison with standard computer programs. Clin Exp Pharmacol Physiol 1985: 9, 95.
6. Ged C, Umbenhauer DR, Bellew TM, Bork RM, Srivastava PK, Shinriki N, Lloyd RS, Guengerich FP. Characterization of cDNAs, mRNAs and proteins related to human liver microsomal cytochrome P-450 (S)-mephenytoin 4′-hydroxylase. Biochemistry 1988: 27, 6929-6940.
7. Goldstein JA, Faletto MB, Romkes-Sparks M, Sullivan T, Litareewan S, Raucy JL, Lasker JM, Ghanayem BI. Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans. Biochemistry 1994: 33, 1743-1754.
8. Gonzalez FJ, Meyer UA. Molecular genetics of the debrisoquin-sparteine polymorphism. Clin Pharmacol Ther 1991: 50, 110-115.
9. Gonzalez FJ, Idle JR. Pharmacogenetic phenotyping and genotyping: present status and futue potential. Clin Pharmacokinetics 1994: 26, 59-70.
10. Gonzalez FJ, Skoda RC, Kimura S, Umeno M, Zanger UM, Nebert DW, Gelboin HV, Hardwick JP, Meyer UA. Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature 1988: 331, 442-446.
11. Gotoh S. Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences. J Biol Chem 1991: 267, 85-90.
12. Gough AC, Miles JS, Spurr NK, Moss JE, Gaedigk A, Eichelbaum M, Wolf CR. Identification of the primary gene defect at the cytochrome P450 CYP2D locus. Nature 1990: 347, 773-776.
13. Holford NHG, MK Model: A modelling tool for microcomputers. Clin Exp Pharmacol Physiol 1995: 9(suppl), 95.
14. Kaminsky LS, de Morais SMF, Faletto MB, Dunbar D, Goldstein JA. Correlation of human P4502C substrate specificities with primary structure - warfarin as a probe. Mol Pharmacol 1993: 43, 234-239.
15. Kimura S, Pastewka J, Gelboin HV, Gonzalez FJ. cDNA and amino acid sequences of two members of the human p450IIC gene subfamily. Nucl Acids Res 1987: 15, 10053-10054.
16. Leeman T, Transon C, Dayer P. Cytochrome P450TB (CYP2C): A major monooxygenase catalysing diclofenac 4′-hydroxylation in human liver. Life Sci 1993: 52, 29-34.
17. McKinnon RA, Hull PDLM. Quattrochi LC, Tukey RH, McManus ME. Localisation of CYP1A1 and CYP1A2 messenger RNA in normal liver and in hepatocellular carcinoma by in situ hybridization. Hepatology 1991: 14, 848-856.
18. Miners JO, Smith KJ, Robson RA, McManus ME, Veronese ME, Birkett DJ. Tolbutamide hydroxylation by human liver microsomes: kinetic characterisation and relationship to other cytochrome P450 dependent xenobiotic oxidations. Biochem Pharmacol 1988: 37, 1137-1144.
19. Miners JO, Wing LMH, Birkett DJ. Normal metabolism of debrisoquine and theophylline in a slow tolbutamide metaboliser. Aust NZ J Med 1985: 15, 348-349.
20. Miners JO, Rees DLP, Valente L, Veronese ME, Birkett DJ. Human hepatic cytochrome P450 2C9 catalyses the rate-limiting pathway of torsemide metabolism. J Pharmacol Exp Ther 1995: 272, 1076-1081.
21. Polous TL, Finzel BC, Howard AJ. High-resolution crystal structure of cytochrome P450cam. J Mol Biol 1989: 195, 687-700.
22. Rettie AE, Korzekwa LR, Kunze KL, Lawrence RF, Eddy AC, Aoyama T, Gelboin HV, Gonzalez FJ, Trager WF. Hydroxylation of warfarin by human cDNA-expressed cytochrome P450: A role for P4502C9 in the etiology of S-warfarin-drug interactions. Chem Res Toxicol 1992: 5, 54-59.
23. Rettie A, Wienkers LC, Gonzales FJ, Trager WF, Korzekwa KR. Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics 1994: 4, 39-42.
24. Robson RA, Matthews AP, Miners JO, McManus ME, Meyer UA, de la Hall PM, Birkett DJ. Characterization of theophylline metabolism in human liver microsomes. Br J Clin Pharmacol 1987: 24, 293-300.
25. Romkes M, Faletto MB, Blaisdell JA, Raucy JL, Goldstein JA, Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily. Biochemistry 1991: 30, 3247-3255.
26. Smith JD, Brinton EA, Breslow JL. Polymorphism in the human apolipoprotein A-I gene promoter region. Association of the minor allele with decreased production rate in vivo and promoter acitivity in vitro. J Clin Invest 1992: 89, 1796-1800.
27. Strauss WM. Preparation of genomic DNA from mammalian tissue. In: Ausubel FM, Brent R, Kingston RE, Moore DD, Seidman JG, Smith JA, Struhe K., eds. Current protocols in molecular biology. J. Wiley & Sons, Inc., 1994.
28. Sullivan-Klose TH, Ghanayem BI, Bell DA, Zhang Z-Y, Kaminsky LS, Shenfield GM, Miners JO, Birkett DJ, Goldstein JA. The role of the CYP2C9-Leu 359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 1996: 6, 341-349.
29. Top B, Van den Boorn N, Van der Zee A, Havekes LM, Frants RR. Detection of allele-specific transcripst by the polymerase chain reaction. Biochem Biophys Res Commun 1991: 178, 1319-1325.
30. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 1979: 76, 4350-4354.
31. Umbenhauer DR, Martin MV, Lloyd RS, Guengerich FP. Cloning and sequence determination of a complementary DNA related to human liver microsomal cytochrome P450 S-mephenytoin 4′-hydroxylase. Biochemistry 1987:26, 1094-1099.
32. Veronese ME, Doecke CJ, Mackenzie PI, McManus ME, Rees DLP, Gasser R, Meyer UA, Miners JO, Birkett DJ. Site-directed mutation studies of human liver cytochrome P-450 isoenzymes in the CYP2C subfamily. Biochem J 1993: 289, 533-538.
33. Wang SL, Huang JD, Lai MD, Tsai JJ. Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese. Pharmacogenetics 1995: 5, 37-42.
34. Yasumori T, Kawano S, Nagata K, Shimada M, Yamazoe Y, Kata R. Nucleotide sequence of a human liver cytochrome P450 related to the rate male specific form. J Biochem (Tokyo) 1987: 102, 1075-1082.